NASDAQ NMS - GLOBAL MARKET · XNCR
+0.53% · +$0.1300 · Vol 5.2M
Market closed · last close 4:00 PM ET · price as of 16:37:16 ET
Xencor Inc

Xencor Inc

Biotechnology
$24.72
Card
Relationship Map

Follow $XNCR

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $XNCR by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Analyst data unavailable at compute time · Sentiment absence reason unknown
XNCR
Xencor Inc
Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Sat Sep 19 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is XNCR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading XNCR catalysts
About Xencor Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2013
Employees
260
Country
US

Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$24.45
Day high
$25.02
Day low
$24.13
Previous close
$24.59
52W high
$29.30
-15.63% from high
52W low
$10.29
76% of range
Market cap
$1.8B
EPS
$-2.4900
Beta
0.55
Shares out
74.4M
Volume
5.2M
3.56× rel vol
Avg volume
1.5M
VWAP
$24.69
Price history computed in-house
1W
+1.27%
1M
-8.44%
3M
+95.57%
1Y
+140.23%
YTD
+61.46%
SMA 50 $22.66 · above
SMA 200 $15.50 · above
52W position 76%

XNCR overview

Veridion Score
59
Registered · 2026-09-18
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around XNCR.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading XNCR Form 4 filings
Public disclosures

Congress activity in XNCR

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for XNCR in the cached public ledger.

Federal contracts

XNCR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for XNCR in this window.
Lobbying spend

XNCR lobbying filings, year to date.

Registered lobbying filings matched to Xencor Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for XNCR in this window.
Loading news for XNCR
Analyst ratings
Sovereign unlock shows live analyst consensus for XNCR.
Options
Sovereign unlock shows live options positioning for XNCR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.